PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Healthcare reforms in Japan
PART 06: Regulatory landscape in Japan
- ASRM
- PMD Act
PART 07: Reimbursement scenario
- Reimbursement scenario for regenerative medicine in Japan
PART 08: Gene therapy: An emerging field in regenerative medicine
PART 09: Pipeline portfolio
PART 10: Market landscape
- Market overview
- Five forces analysis
PART 11: Market segmentation by product
- Cell therapy
- Cell therapy regenerative medicine market in Japan
- Tissue scaffold
- Tissue scaffold regenerative medicine market in Japan
PART 12: Market segmentation by application
- Dermatology
- Musculoskeletal
- Cardiovascular
- Other
PART 13: Market drivers
- Transformation of regulatory landscape fostering quick approval of regenerative medicines
- Growing partnerships of MNCs with local vendors in Japan
- Recent product approvals fuel the market growth
- Government initiatives driving regenerative medicine market in Japan
PART 14: Impact of drivers
PART 15: Market challenges
- Ethical challenges involved in regenerative medicine
- High cost and failure rate in clinical trials coupled with inadequate clinical evidence
- Low competitive edge of Japanese regenerative medicine market over other developed nations
PART 16: Impact of drivers and challenges
PART 17: Market trends
- Strong pipeline portfolio of regenerative medicines
- Entry of new players expanding the applications of regenerative medicine
- Strategic collaborations and acquisitions
- Advent of 3D tissue bioprinters for the development of regenerative medicines
PART 18: Vendor landscape
- Competitive scenario
- Key news
- Product approvals
- Partnerships
- Mergers and acquisitions
- Other
PART 19: Key vendor analysis
- CellSeed
- JCR Pharmaceuticals
- Japan Tissue Engineering (J-TEC)
- Terumo
- Upcoming vendors
- Other prominent vendors
PART 20: Appendix
- List of abbreviations
PART 21: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Regenerative medicine application in various therapeutics
Exhibit 03: Major applications of regenerative medicine in Japan
Exhibit 04: Regenerative medicine legislation acts in Japan
Exhibit 05: Product approval and regulatory characteristics in Japan
Exhibit 06: Overview of regenerative medicine regulation acts
Exhibit 07: Landscape of regenerative medicine in Japan
Exhibit 08: Risk categories of regenerative medical technologies
Exhibit 09: Regenerative medicine approval process in Japan under the ASRM
Exhibit 10: Regenerative medicine approval process in Japan under PMD Act
Exhibit 11: Comparison of traditional and new product approval process under the PMD Act
Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals
Exhibit 13: Japan's NHI pricing methods
Exhibit 14: NHI pricing calculation for TEMCELL HS
Exhibit 15: NHI pricing calculation for HeartSheet A kit
Exhibit 16: NHI pricing calculation for HeartSheet B kit
Exhibit 17: Gene therapy research by sponsorship
Exhibit 18: Regenerative medicine pipeline products in Japan
Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015
Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015
Exhibit 21: Key developments in regenerative medicine market in Japan 2015
Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020
Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020
Exhibit 25: Five forces analysis
Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020
Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015
Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015
Exhibit 29: Cell therapy overview
Exhibit 30: Ethical issues involved in different cell therapy research category
Exhibit 31: Stem cell research policies in Japan
Exhibit 32: Key cell therapy products marketed in Japan
Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan
Exhibit 35: Collaborations for R&D of tissue scaffold
Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market
Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions)
Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%)
Exhibit 40: Overview of the regenerative medicine dermatology market in Japan
Exhibit 41: Pipeline of regenerative medicine for dermatology
Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan
Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan
Exhibit 44: Regulatory guidelines in Japan
Exhibit 45: Approval process of SAKIGAKE assignment system
Exhibit 46: Partnerships of MNCs with local vendors in Japan
Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions)
Exhibit 48: Impact of drivers
Exhibit 49: Force field analysis of regenerative medicine market in Japan
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Regenerative medicine pipeline portfolio 2015
Exhibit 52: Current applications of regenerative medicine
Exhibit 53: Future applications of regenerative medicine
Exhibit 54: Major strategic collaborations and acquisitions in Japan
Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020
Exhibit 56: Presence of vendors in regenerative medicine
Exhibit 57: CellSeed: Profile
Exhibit 58: CellSeed: Strength analysis
Exhibit 59: CellSeed: Growth strategy matrix
Exhibit 60: CellSeed: Opportunity assessment
Exhibit 61: JCR Pharmaceuticals: Profile
Exhibit 62: JCR Pharmaceuticals: Strength analysis
Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix
Exhibit 64: JCR Pharmaceuticals: Opportunity assessment
Exhibit 65: J-TEC: Profile
Exhibit 66: J-TEC: Strength analysis
Exhibit 67: J-TEC: Growth strategy matrix
Exhibit 68: J-TEC: Opportunity assessment
Exhibit 69: Terumo: Profile
Exhibit 70: Terumo: Strength analysis
Exhibit 71: Terumo: Growth strategy matrix
Exhibit 72: Terumo: Opportunity assessment